Loading
Life sciences · Journal article
Nature Communications · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Many solid tumors remain refractory to immunotherapy due to profoundly immunosuppressive tumor microenvironments. Although vagus nerve stimulation offers a direct neural axis to reprogram immune function, its potential in cancer immunotherapy remains unrealized due to the absence of stable, system-level neuromodulation platforms. Herein, we develop a miniature subdiaphragmatic vagus nerve stimulator (SVNS) for near-organ neuromodulation of pancreatic tumor immunity. To construct stable electrical coupling with subdiaphragmatic vagus nerve (SVN) along the esophagus, a dynamically adaptive neural interface comprising an injectable anti-fatigue adhesive conductive hydrogel and a deformable liquid metal electrode is explored. The SVNS is integrated with a battery-free lead-free wireless power module, which can be configured into a Swiss-roll architecture, enabling minimally invasive implantation. In an orthotopic mouse model of pancreatic tumor, chronic SVN stimulation using SVNS suppressed tumor growth and metastasis, reshaped tumor innervation, promoted a shift toward an M1-like TAM phenotype, enhanced cytotoxic immune cell infiltration, and further potentiated the efficacy of anti-PD-1 immunotherapy.